ATI-1428ATI-1428: Best in class potential CAM

ATI-1428 has entered IND enabling development

Derived from a novel chemical scaffold, ATI-1428 has shown strong in vitro and in vivo activity in a transgenic mouse model of hepatitis B virus (HBV) infection.1

Early in vivo data point to a differentiated mechanism of action (MOA) which prevents accumulation of empty capsids, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1

ATI-1428 has been identified as a 4th generation sub-nM potent compounds from a novel series of class II CAMs.1

Derived from a novel chemical scaffold, ATI-1428 shows safe and potent in vitro and in vivo activity, as well as an excellent PK and developability profile.1

Early in vivo data point to a differentiated MOA which prevents accumulation of empty capsids in the hepatocellular cytoplasm, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1

ATI-1428 displays strong antiviral activity against naturally occurring variants and low EC50 shift against variants associated with resistance to past and current CAMs​.1

Why ATI-1428?

ATI-1428 results in more potent viral suppression than earlier generations, as measured by 2 key markers of HBV replication1

ATI-1428 deeply inhibits HBV replication and prevent cccDNA establishment without causing liver damage.1

Our CAMs have the potential to synergize with our ASPIN, ATI-2173, and target different stages of the HBV life cycle.1

Watch CAM MOA Video

ATI-1428 selected for unique mechanism of action1

  • Traditional CAMs being developed by others induce retention of hepatitis B core antigen (HBcAg), while Antios’ proprietary novel CAMs (ATI-1428 and ATI-1645) do not1
  • The retention of HBcAg empty capsid could be a clinical safety liability and a decoy for functional immune-based clearance1
  • Competitor CAMs have on- and off-treatment ALT flares in their clinical programs1

ATI-1428 is the next step in our mission to create a world without HBV.

Find out more

Reference: 1. Data on file. Antios Therapeutics, Doylestown, PA.

Improving lives through the treatment of HBV About our therapies